胃がんの世界市場：タイプ別、病期別、薬剤クラス別、診断別、治療別、投与経路別、流通チャネル別、エンドユーザー別、地域別、機会、予測、2017年～2031年

世界の胃がんの市場規模は2023年に48億7,000万米ドルとなりました。同市場は、2031年には128億3,000万米ドルに達するとみられ、2024年から2031年の予測期間に12.88％のCAGRで拡大すると予測されています。世界の胃がん市場は、胃がんの診断、治療、研究に関わる包括的な市場です。胃がんは世界的に重大な健康問題であり、医学的、経済的、社会的に大きな負担となっています。この市場は、革新的な治療法、診断ツール、支持療法、この病気に関連する課題に対処するための進行中の臨床研究など、幅広い活動を包含しています。胃がん市場における進歩は、主に早期発見技術、個別化された治療オプション、患者の転帰の改善に焦点を当てています。

診断手技には、内視鏡検査、画像技術、分子診断検査が含まれ、病気を初期段階で特定し、治療の成功率に大きく影響します。市場の情勢は、新たな治療アプローチの出現と最先端技術の統合により、絶えず進化しています。免疫療法、プレシジョンメディシン、併用療法など、革新的な治療法を模索する臨床試験や研究イニシアチブが進行中です。製薬会社、研究機関、ヘルスケアプロバイダーの協力は、胃がんに対する理解を深め、より効果的で的を絞った治療法を開発するために不可欠です。さらに、認知度の向上、早期発見、危険因子や症状に関する教育の提供を目的とした取り組みが、世界規模での胃がん管理全般に重要な役割を果たしています。進化する胃がん市場の状況は、患者の転帰を改善する可能性を秘め、この分野における継続的な調査、革新、協力の重要性を強調しています。

世界の胃がん市場は近年、革新的な技術や治療アプローチに牽引され、大きな進歩を遂げています。注目すべき技術革新のひとつは、精密医療と、腫瘍の特定の分子的特徴に基づいて個々の患者に合わせた標的療法の出現です。チェックポイント阻害剤などの免疫療法は、がん細胞に対する身体の免疫反応を強化することで、一部の症例で有望視されています。さらに、ロボット支援手術を含む低侵襲手術技術の進歩により、治療成績が向上し、患者の不快感や回復時間が短縮されました。

診断ツールも進化しており、胃がんの早期発見とモニタリングのためのリキッドバイオプシーが開発されました。これらの検査は、循環腫瘍DNAを分析する侵襲性の低い方法を提供し、より迅速な介入と個別化された治療戦略を可能にする可能性があります。例えば、2023年1月、エーザイ株式会社は、カリフォルニア州サンフランシスコで開催された2023年米国臨床腫瘍学会（ASCO）の消化器がんに関するシンポジウム（#GI23）において、多様な消化器がん種を対象とした研究を紹介することを発表しました。

当レポートでは、世界の胃がん市場について調査し、市場の概要とともに、タイプ別、病期別、薬剤クラス別、診断別、治療別、投与経路別、流通チャネル別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 COVID-19が世界の胃がん市場に与える影響

第4章 エグゼクティブサマリー

第5章 世界の胃がん市場の見通し、2017年～2031年

• 市場規模と予測
• タイプ別
• 病期別
• 薬剤クラス別
• 診断別
• 治療別
• 投与経路別
• 流通チャネル別
• エンドユーザー別
• 地域別
• 企業別市場シェア（%）、2023年

第6章 世界の胃がん市場の見通し、地域別、2017年～2031年

• 北米
• 欧州
• 南米
• アジア太平洋
• 中東・アフリカ

第7章 市場マッピング、2023年

第8章 マクロ環境と産業構造

• 需給分析
• 輸出入分析- 量と金額
• サプライ/バリューチェーン分析
• PESTEL分析
• ポーターのファイブフォース分析

第9章 市場力学

第10章 規制の枠組みとイノベーション

第11章 主要参入企業の情勢

第12章 価格分析

第13章 ケーススタディ

第14章 主要企業の見通し

• Novartis AG
• F. Hoffmann-La Roche Ltd.
• Bristol Myers Squibb Company
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Pfizer, Inc.
• Mylan N.V.
• Merck & Co., Inc.
• Sanofi, Bayer AG
• Johnson & Johnson Private Limited
• Cipla Inc.
• AbbVie Inc.
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma
• Hikma Pharmaceuticals PLC

第15章 戦略的提言

第16章 お問合せと免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 2. Global Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 3. Global Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 4. Global Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 5. Global Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 6. Global Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 7. Global Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 8. Global Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 9. Global Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 10. Global Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 11. Global Gastric Cancer Market Share (%), By Region, 2017-2031F
• Figure 12. North America Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 13. North America Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 14. North America Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 15. North America Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 16. North America Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 17. North America Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 18. North America Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 19. North America Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 20. North America Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 21. North America Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 22. North America Gastric Cancer Market Share (%), By Country, 2017-2031F
• Figure 23. United States Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 24. United States Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 25. United States Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 26. United States Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 27. United States Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 28. United States Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 29. United States Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 30. United States Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 31. United States Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 32. United States Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 33. Canada Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 34. Canada Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 35. Canada Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 36. Canada Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 37. Canada Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 38. Canada Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 39. Canada Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 40. Canada Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 41. Canada Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 42. Canada Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 43. Mexico Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 44. Mexico Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 45. Mexico Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 46. Mexico Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 47. Mexico Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 48. Mexico Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 49. Mexico Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 50. Mexico Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 51. Mexico Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 52. Mexico Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 53. Europe Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 54. Europe Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 55. Europe Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 56. Europe Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 57. Europe Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 58. Europe Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 59. Europe Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 60. Europe Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 61. Europe Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 62. Europe Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 63. Europe Gastric Cancer Market Share (%), By Country, 2017-2031F
• Figure 64. Germany Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 65. Germany Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 66. Germany Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 67. Germany Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 68. Germany Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 69. Germany Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 70. Germany Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 71. Germany Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 72. Germany Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 73. Germany Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 74. France Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 75. France Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 76. France Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 77. France Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 78. France Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 79. France Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 80. France Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 81. France Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 82. France Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 83. France Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 84. Italy Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 85. Italy Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 86. Italy Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 87. Italy Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 88. Italy Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 89. Italy Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 90. Italy Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 91. Italy Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 92. Italy Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 93. Italy Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 94. United Kingdom Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 95. United Kingdom Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 96. United Kingdom Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 97. United Kingdom Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 98. United Kingdom Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 99. United Kingdom Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 100. United Kingdom Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 101. United Kingdom Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 102. United Kingdom Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 103. United Kingdom Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 104. Russia Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 105. Russia Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 106. Russia Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 107. Russia Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 108. Russia Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 109. Russia Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 110. Russia Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 111. Russia Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 112. Russia Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 113. Russia Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 114. Netherlands Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 115. Netherlands Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 116. Netherlands Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 117. Netherlands Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 118. Netherlands Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 119. Netherlands Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 120. Netherlands Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 121. Netherlands Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 122. Netherlands Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 123. Netherlands Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 124. Spain Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 125. Spain Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 126. Spain Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 127. Spain Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 128. Spain Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 129. Spain Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 130. Spain Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 131. Spain Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 132. Spain Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 133. Spain Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 134. Turkey Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 135. Turkey Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 136. Turkey Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 137. Turkey Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 138. Turkey Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 139. Turkey Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 140. Turkey Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 141. Turkey Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 142. Turkey Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 143. Turkey Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 144. Poland Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 145. Poland Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 146. Poland Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 147. Poland Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 148. Poland Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 149. Poland Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 150. Poland Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 151. Poland Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 152. Poland Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 153. Poland Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 154. South America Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 155. South America Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 156. South America Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 157. South America Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 158. South America Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 159. South America Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 160. South America Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 161. South America Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 162. South America Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 163. South America Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 164. South America Gastric Cancer Market Share (%), By Country, 2017-2031F
• Figure 165. Brazil Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 166. Brazil Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 167. Brazil Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 168. Brazil Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 169. Brazil Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 170. Brazil Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 171. Brazil Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 172. Brazil Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 173. Brazil Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 174. Brazil Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 175. Argentina Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 176. Argentina Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 177. Argentina Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 178. Argentina Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 179. Argentina Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 180. Argentina Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 181. Argentina Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 182. Argentina Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 183. Argentina Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 184. Argentina Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 185. Asia-Pacific Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 186. Asia-Pacific Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 187. Asia-Pacific Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 188. Asia-Pacific Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 189. Asia-Pacific Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 190. Asia-Pacific Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 191. Asia-Pacific Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 192. Asia-Pacific Gastric Cancer Market Share (%), By Route of Administration, 2016-2030
• Figure 193. Asia-Pacific Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 194. Asia-Pacific Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 195. Asia-Pacific Gastric Cancer Market Share (%), By Country, 2017-2031F
• Figure 196. India Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 197. India Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 198. India Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 199. India Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 200. India Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 201. India Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 202. India Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 203. India Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 204. India Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 205. India Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 206. China Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 207. China Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 208. China Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 209. China Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 210. China Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 211. China Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 212. China Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 213. China Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 214. China Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 215. China Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 216. Japan Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 217. Japan Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 218. Japan Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 219. Japan Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 220. Japan Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 221. Japan Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 222. Japan Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 223. Japan Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 224. Japan Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 225. Japan Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 226. Australia Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 227. Australia Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 228. Australia Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 229. Australia Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 230. Australia Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 231. Australia Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 232. Australia Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 233. Australia Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 234. Australia Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 235. Australia Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 236. Vietnam Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 237. Vietnam Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 238. Vietnam Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 239. Vietnam Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 240. Vietnam Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 241. Vietnam Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 242. Vietnam Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 243. Vietnam Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 244. Vietnam Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 245. Vietnam Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 246. South Korea Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 247. South Korea Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 248. South Korea Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 249. South Korea Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 250. South Korea Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 251. South Korea Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 252. South Korea Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 253. South Korea Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 254. South Korea Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 255. South Korea Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 256. Indonesia Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 257. Indonesia Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 258. Indonesia Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 259. Indonesia Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 260. Indonesia Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 261. Indonesia Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 262. Indonesia Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 263. Indonesia Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 264. Indonesia Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 265. Indonesia Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 266. Philippines Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 267. Philippines Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 268. Philippines Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 269. Philippines Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 270. Philippines Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 271. Philippines Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 272. Philippines Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 273. Philippines Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 274. Philippines Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 275. Philippines Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 276. Middle East & Africa Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 277. Middle East & Africa Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 278. Middle East & Africa Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 279. Middle East & Africa Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 280. Middle East & Africa Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 281. Middle East & Africa Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 282. Middle East & Africa Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 283. Middle East & Africa Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 284. Middle East & Africa Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 285. Middle East & Africa Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 286. Middle East & Africa Gastric Cancer Market Share (%), By Country, 2017-2031F
• Figure 287. Saudi Arabia Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 288. Saudi Arabia Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 289. Saudi Arabia Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 290. Saudi Arabia Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 291. Saudi Arabia Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 292. Saudi Arabia Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 293. Saudi Arabia Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 294. Saudi Arabia Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 295. Saudi Arabia Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 296. Saudi Arabia Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 297. UAE Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 298. UAE Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 299. UAE Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 300. UAE Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 301. UAE Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 302. UAE Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 303. UAE Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 304. UAE Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 305. UAE Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 306. UAE Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 307. South Africa Gastric Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 308. South Africa Gastric Cancer Market, By Volume, In Millions, 2017-2031F
• Figure 309. South Africa Gastric Cancer Market Share (%), By Type, 2017-2031F
• Figure 310. South Africa Gastric Cancer Market Share (%), By Stages, 2017-2031F
• Figure 311. South Africa Gastric Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 312. South Africa Gastric Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 313. South Africa Gastric Cancer Market Share (%), By Treatment, 2017-2031F
• Figure 314. South Africa Gastric Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 315. South Africa Gastric Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 316. South Africa Gastric Cancer Market Share (%), By End-users, 2017-2031F
• Figure 317. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 318. By Stages Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 319. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 320. By Diagnosis Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 321. By Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 322. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 323. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 324. By End-users Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 325. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Global gastric cancer market size was valued at USD 4.87 billion in 2023, which is expected to reach USD 12.83 billion in 2031, growing with a CAGR of 12.88% for the forecast period between 2024 and 2031F. The global gastric cancer market pertains to a comprehensive landscape involving the diagnosis, treatment, and research dedicated to gastric (stomach) cancer. Gastric cancer is a significant health concern worldwide, it poses a considerable medical, economic, and social burden. The market encompasses a broad spectrum of activities, including innovative therapies, diagnostic tools, supportive care, and ongoing clinical research to address the challenges associated with the disease. Advancements in the gastric cancer market primarily focus on early detection techniques, personalized treatment options, and improving patient outcomes.

Diagnostic procedures involve endoscopic examinations, imaging technologies, and molecular diagnostic tests to identify the disease at its initial stages, significantly impacting treatment success rates. The market's landscape is continually evolving due to the emergence of novel therapeutic approaches and the integration of cutting-edge technologies. Clinical trials and research initiatives are ongoing, exploring innovative treatment options, including immunotherapies, precision medicines, and combination therapies. Collaboration between pharmaceutical companies, research institutions, and healthcare providers is critical for advancing the understanding of gastric cancer and developing more effective and targeted therapies. Additionally, initiatives aimed at raising awareness, early detection, and providing education about risk factors and symptoms play a crucial role in the overall management of gastric cancer on a global scale. The evolving landscape of gastric cancer market holds promise for improved patient outcomes, emphasizing the importance of continued research, innovation, and collaboration in the field.

New Innovations

The global gastric cancer market has seen significant advancements in recent years, driven by innovative technologies and treatment approaches. One notable innovation involves the emergence of precision medicine and targeted therapies tailored to individual patients based on specific molecular characteristics of their tumors. Immunotherapies, such as checkpoint inhibitors, have shown promise in some cases by enhancing the body's immune response against cancer cells. Additionally, advancements in minimally invasive surgical techniques, including robotic-assisted surgery, have improved treatment outcomes, reducing patient discomfort and recovery times.

Diagnostic tools too have evolved, with the development of liquid biopsies for early detection and monitoring of gastric cancer. These tests offer a less invasive method to analyze circulating tumor DNA, potentially allowing for quicker intervention and personalized treatment strategies. For instance, in January 2023, Eisai Co., Ltd. announced the showcasing of their research covering diverse gastrointestinal cancer types at the 2023 American Society of Clinical Oncology (ASCO) symposium on gastrointestinal cancers (#GI23), held in San Francisco, California.

Growing Regulatory Landscape

The Global Gastric Cancer Market product approvals are increasing due to the complex nature of these diseases. The increase in product approvals, collaboration, and innovation are pivotal. Research institutions, pharmaceutical companies, and regulatory bodies are collaborating closely to streamline clinical trials and expedite the approval process. Furthermore, investing in technological advancements like precision medicine and immunotherapy significantly enhances treatment outcomes, leading to more successful drug approvals.

For instance, in March 2023, Akeso, Inc., finalized the enrolment of patients for its crucial Phase III clinical trial for cadonilimab (AK104), a groundbreaking PD-1/CTLA-4 bi-specific antibody. The achievement represents a significant milestone as it is the first dual-immune checkpoint bi-specific antibody drug to receive approval and enter the market. The advancement brings cadonilimab one step closer to its official launch for a major indication following the successful approval for the treatment of cervical cancer.

Strategic Partnership Between Key Players

A strategic partnership between key players in global gastric cancer market holds significant promise for advancing the diagnosis, treatment, and overall management of the prevalent malignancy. Such collaborations can leverage the combined expertise and resources of pharmaceutical companies, research institutions, and healthcare providers to address the multifaceted challenges gastric cancer poses. These partnerships can accelerate the development of innovative therapies, diagnostic tools, and treatment protocols, ultimately improving patient outcomes. By pooling their knowledge and capabilities, stakeholders can better understand gastric cancer molecular underpinnings and optimize clinical trial designs, potentially leading to more effective and targeted treatments. Additionally, partnerships can facilitate early detection and screening programs, thereby increasing the chances of early intervention, and reducing the global burden of gastric cancer.

For instance, during February 2022, Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb entered a contract with Prime Research Institute for Medical RWD, Inc. This agreement aimed to conduct extensive, industry-sponsored, multi-institutional clinical research involving patients with gastric cancer. The study focused on the treatment involving Opdivo in conjunction with chemotherapy.

Development of Precision Medicine

Precision medicine in the global gastric cancer market has significantly advanced, leveraging individual patient variability in genes, environment, and lifestyle for tailored treatment. Innovations like next-generation sequencing, biomarker identification, and molecular profiling have revolutionized diagnosis and therapy selection. Targeted therapies, like trastuzumab for HER2-positive tumors, exemplify precision medicine's impact by improving patient outcomes. Companion diagnostics enables patients to respond to specific treatments, optimizing efficacy, and reducing adverse effects. The integration of big data analytics and artificial intelligence further refines treatment strategies, predicting responses and disease progression.

However, challenges such as cost, accessibility, and data interpretation persist, hindering widespread implementation. For instance, according to an article published in July 2022 in PubMed, the progress of precision medicine has continuously received substantial support from the remarkable strides achieved in both local and global studies concerning molecular targeted therapy for gastric cancer in recent years.

Impact of COVID-19

The global healthcare systems were widely impacted by the COVID-19 pandemic, significantly influencing the market for gastric cancer therapy. The diagnosis and treatment of gastric cancer experienced delays or cancellations owing to the worldwide lockdown measures. For example, a March 2023 article in PubMed highlighted how during the initial period of the pandemic, the care of gastric cancer patients worldwide suffered due to reduced multidisciplinary team meetings and a decline in elective gastrectomy. Amid the COVID-19 pandemic, delays in diagnosing and treating cancer placed patients at risk of negative consequences. These delays significantly affected the market's growth due to treatment and diagnosis disruptions. Nevertheless, the market for gastric cancer treatments has now reverted to its pre-pandemic state.

Key Players Landscape and Outlook

The competitive landscape of global gastric cancer market offers comprehensive insights on competitors. These details include company profiles, financial standings, revenue generation, market opportunities, research and development investments, new market strategies, international reach, manufacturing facilities, production capabilities, strengths and weaknesses, product launches, product diversity, and dominant applications. It is important to note that the mentioned data points specifically pertain to the companies' involvement in the global gastric cancer market.

BDR Pharma announced the introduction of Furmecil (recognized as S-1), a composite of three medications-Tegafur, Gimeracil, and Oteracil, in April 2022. Oral medication is specified for treating advanced gastric cancer in adults. According to a statement from BDR Pharma, Furmecil has displayed notable efficacy and a positive safety profile in its use.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19 on Global Gastric Cancer Market

4. Executive Summary

5. Global Gastric Cancer Market Outlook, 2017-2031F

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
  • 5.1.2. By Volume
• 5.2. By Type
  • 5.2.1. Adenocarcinoma
  • 5.2.2. Lymphoma
  • 5.2.3. Gastrointestinal Stromal Tumor
  • 5.2.4. Carcinoid Tumor
  • 5.2.5. Others
• 5.3. By Stages
  • 5.3.1. Stage I
  • 5.3.2. Stage II
  • 5.3.3. Stage III
  • 5.3.4. Stage IV
  • 5.3.5. Others
• 5.4. By Drug Class
  • 5.4.1. PD-1/PD-L1 Inhibitors
  • 5.4.2. HER2 Antagonists
  • 5.4.3. VEGFR2 Antagonists
  • 5.4.4. Others
• 5.5. By Diagnosis
  • 5.5.1. Endoscopy
  • 5.5.2. Biopsy
  • 5.5.3. Imaging Tests
  • 5.5.4. Exploratory Surgery
  • 5.5.5. Other
• 5.6. By Treatment
  • 5.6.1. Surgery
  • 5.6.2. Radiation Therapy
  • 5.6.3. Chemotherapy
  • 5.6.4. Targeted Therapy
  • 5.6.5. Palliative Care
  • 5.6.6. Others
• 5.7. By Route of Administration
  • 5.7.1. Oral
  • 5.7.2. Parenteral
  • 5.7.3. Others
• 5.8. By Distribution Channel
  • 5.8.1. Hospital Pharmacy
  • 5.8.2. Online Pharmacy
  • 5.8.3. Retail Pharmacy
• 5.9. By End-users
  • 5.9.1. Hospitals
  • 5.9.2. Homecare
  • 5.9.3. Speciality Centres
  • 5.9.4. Others
• 5.10. By Region
  • 5.10.1. North America
  • 5.10.2. Europe
  • 5.10.3. Asia Pacific
  • 5.10.4. South America
  • 5.10.5. Middle East & Africa
• 5.11. By Company Market Share (%), 2023

6. Global Gastric Cancer Market Outlook, By Region, 2017-2031F

• 6.1. North America*
  • 6.1.1. Market Size & Forecast
    • 6.1.1.1. Value
    • 6.1.1.2. Volume
  • 6.1.2. By Type
    • 6.1.2.1. Adenocarcinoma
    • 6.1.2.2. Lymphoma
    • 6.1.2.3. Gastrointestinal Stromal Tumor
    • 6.1.2.4. Carcinoid Tumor
    • 6.1.2.5. Others
  • 6.1.3. By Stages
    • 6.1.3.1. Stage I
    • 6.1.3.2. Stage II
    • 6.1.3.3. Stage III
    • 6.1.3.4. Stage IV
    • 6.1.3.5. Others
  • 6.1.4. By Drug Class
    • 6.1.4.1. PD-1/PD-L1 Inhibitors
    • 6.1.4.2. HER2 Antagonists
    • 6.1.4.3. VEGFR2 Antagonists
    • 6.1.4.4. Others
  • 6.1.5. By Diagnosis
    • 6.1.5.1. Endoscopy
    • 6.1.5.2. Biopsy
    • 6.1.5.3. Imaging Tests
    • 6.1.5.4. Exploratory Surgery
    • 6.1.5.5. Other
  • 6.1.6. By Treatment
    • 6.1.6.1. Surgery
    • 6.1.6.2. Radiation Therapy
    • 6.1.6.3. Chemotherapy
    • 6.1.6.4. Targeted Therapy
    • 6.1.6.5. Palliative Care
    • 6.1.6.6. Others
  • 6.1.7. By Route of Administration
    • 6.1.7.1. Oral
    • 6.1.7.2. Parenteral
    • 6.1.7.3. Others
  • 6.1.8. By Distribution Channel
    • 6.1.8.1. Hospital Pharmacy
    • 6.1.8.2. Online Pharmacy
    • 6.1.8.3. Retail Pharmacy
  • 6.1.9. By End-users
    • 6.1.9.1. Hospitals
    • 6.1.9.2. Homecare
    • 6.1.9.3. Speciality Centres
    • 6.1.9.4. Others
  • 6.1.10. United States*
    • 6.1.10.1. Market Size & Forecast
    • 6.1.10.1.1. Value
    • 6.1.10.1.2. Volume
    • 6.1.10.2. By Type
    • 6.1.10.2.1. Adenocarcinoma
    • 6.1.10.2.2. Lymphoma
    • 6.1.10.2.3. Gastrointestinal Stromal Tumor
    • 6.1.10.2.4. Carcinoid Tumor
    • 6.1.10.2.5. Others
    • 6.1.10.3. By Stages
    • 6.1.10.3.1. Stage I
    • 6.1.10.3.2. Stage II
    • 6.1.10.3.3. Stage III
    • 6.1.10.3.4. Stage IV
    • 6.1.10.3.5. Others
    • 6.1.10.4. By Drug Class
    • 6.1.10.4.1. PD-1/PD-L1 Inhibitors
    • 6.1.10.4.2. HER2 Antagonists
    • 6.1.10.4.3. VEGFR2 Antagonists
    • 6.1.10.4.4. Others
    • 6.1.10.5. By Diagnosis
    • 6.1.10.5.1. Endoscopy
    • 6.1.10.5.2. Biopsy
    • 6.1.10.5.3. Imaging Tests
    • 6.1.10.5.4. Exploratory Surgery
    • 6.1.10.5.5. Other
    • 6.1.10.6. By Treatment
    • 6.1.10.6.1. Surgery
    • 6.1.10.6.2. Radiation Therapy
    • 6.1.10.6.3. Chemotherapy
    • 6.1.10.6.4. Targeted Therapy
    • 6.1.10.6.5. Palliative Care
    • 6.1.10.6.6. Others
    • 6.1.10.7. By Route of Administration
    • 6.1.10.7.1. Oral
    • 6.1.10.7.2. Parenteral
    • 6.1.10.7.3. Others
    • 6.1.10.8. By Distribution Channel
    • 6.1.10.8.1. Hospital Pharmacy
    • 6.1.10.8.2. Online Pharmacy
    • 6.1.10.8.3. Retail Pharmacy
    • 6.1.10.9. By End-users
    • 6.1.10.9.1. Hospitals
    • 6.1.10.9.2. Homecare
    • 6.1.10.9.3. Speciality Centres
    • 6.1.10.9.4. Others
  • 6.1.11. Canada
  • 6.1.12. Mexico

All segments will be provided for all regions and countries covered:

• 6.2. Europe
  • 6.2.1. Germany
  • 6.2.2. France
  • 6.2.3. Italy
  • 6.2.4. United Kingdom
  • 6.2.5. Russia
  • 6.2.6. Netherlands
  • 6.2.7. Spain
  • 6.2.8. Turkey
  • 6.2.9. Poland
• 6.3. South America
  • 6.3.1. Brazil
  • 6.3.2. Argentina
• 6.4. Asia-Pacific
  • 6.4.1. India
  • 6.4.2. China
  • 6.4.3. Japan
  • 6.4.4. Australia
  • 6.4.5. Vietnam
  • 6.4.6. South Korea
  • 6.4.7. Indonesia
  • 6.4.8. Philippines
• 6.5. Middle East & Africa
  • 6.5.1. Saudi Arabia
  • 6.5.2. UAE
  • 6.5.3. South Africa

7. Market Mapping, 2023

• 7.1. By Type
• 7.2. By Stages
• 7.3. By Drug Class
• 7.4. By Diagnosis
• 7.5. By Treatment
• 7.6. By Route of Administration
• 7.7. By Distribution Channel
• 7.8. By End-users
• 7.9. By Region

8. Macro Environment and Industry Structure

• 8.1. Supply Demand Analysis
• 8.2. Import Export Analysis - Volume and Value
• 8.3. Supply/Value Chain Analysis
• 8.4. PESTEL Analysis
  • 8.4.1. Political Factors
  • 8.4.2. Economic System
  • 8.4.3. Social Implications
  • 8.4.4. Technological Advancements
  • 8.4.5. Environmental Impacts
  • 8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 8.5. Porter's Five Forces Analysis
  • 8.5.1. Supplier Power
  • 8.5.2. Buyer Power
  • 8.5.3. Substitution Threat
  • 8.5.4. Threat from New Entrant
  • 8.5.5. Competitive Rivalry

9. Market Dynamics

• 9.1. Growth Drivers
• 9.2. Growth Inhibitors (Challenges, Restraints)

10. Regulatory Framework and Innovation

• 10.1. Clinical Trials
• 10.2. Patent Landscape
• 10.3. Regulatory Approvals
• 10.4. Innovations/Emerging Technologies

11. Key Players Landscape

• 11.1. Competition Matrix of Top Five Market Leaders
• 11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
• 11.4. SWOT Analysis (For Five Market Players)
• 11.5. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

• 14.1. Novartis AG
  • 14.1.1. Company Details
  • 14.1.2. Key Management Personnel
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As reported)
  • 14.1.5. Key Market Focus & Geographical Presence
  • 14.1.6. Recent Developments
• 14.2. F. Hoffmann-La Roche Ltd.
• 14.3. Bristol Myers Squibb Company
• 14.4. Eli Lilly and Company
• 14.5. Teva Pharmaceutical Industries Ltd.
• 14.6. Pfizer, Inc.
• 14.7. Mylan N.V.
• 14.8. Merck & Co., Inc.
• 14.9. Sanofi, Bayer AG
• 14.10. Johnson & Johnson Private Limited
• 14.11. Cipla Inc.
• 14.12. AbbVie Inc.
• 14.13. Sun Pharmaceutical Industries Ltd.
• 14.14. Aurobindo Pharma
• 14.15. Hikma Pharmaceuticals PLC

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

15. Strategic Recommendations

16. About Us & Disclaimer